One Equity Partners (OEP), the private merchant banking arm of JPMorgan Chase, is estimated to have earned about 2 trillion won ($1.67 billion) in proceeds from the initial 300 billion won invested into the Korean pharmaceutical distributor Celltrion Healthcare eight years ago, The Korea Economic Daily (KED) reported on July 7, citing investment banking sources. 

OEP, which focuses on leveraged buyout and growth capital investments in middle-market companies, offloaded its remaining shares in Celltrion Healthcare valued at approximately 310 billion won through a block deal and earned nearly seven times the amount of its investment, the report said.